Westfield Capital Management Co. LP Boosts Stake in Xenon Pharmaceuticals Inc. $XENE

Westfield Capital Management Co. LP raised its position in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) by 4.6% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,206,066 shares of the biopharmaceutical company’s stock after buying an additional 53,461 shares during the quarter. Westfield Capital Management Co. LP owned about 1.56% of Xenon Pharmaceuticals worth $48,424,000 as of its most recent SEC filing.

Several other hedge funds have also modified their holdings of XENE. TD Asset Management Inc purchased a new position in shares of Xenon Pharmaceuticals in the third quarter valued at $652,000. JPMorgan Chase & Co. lifted its position in Xenon Pharmaceuticals by 11.3% during the third quarter. JPMorgan Chase & Co. now owns 1,399,033 shares of the biopharmaceutical company’s stock valued at $56,171,000 after purchasing an additional 142,452 shares during the last quarter. PNC Financial Services Group Inc. grew its stake in shares of Xenon Pharmaceuticals by 70.4% in the 3rd quarter. PNC Financial Services Group Inc. now owns 5,899 shares of the biopharmaceutical company’s stock worth $237,000 after buying an additional 2,437 shares in the last quarter. Aberdeen Group plc grew its stake in shares of Xenon Pharmaceuticals by 11.1% in the 3rd quarter. Aberdeen Group plc now owns 579,145 shares of the biopharmaceutical company’s stock worth $23,253,000 after buying an additional 57,653 shares in the last quarter. Finally, Assetmark Inc. increased its holdings in shares of Xenon Pharmaceuticals by 6.2% in the 3rd quarter. Assetmark Inc. now owns 22,566 shares of the biopharmaceutical company’s stock worth $906,000 after buying an additional 1,316 shares during the last quarter. 95.45% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

XENE has been the subject of a number of analyst reports. Needham & Company LLC reaffirmed a “buy” rating and issued a $55.00 price target on shares of Xenon Pharmaceuticals in a report on Tuesday, November 4th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Xenon Pharmaceuticals in a research note on Friday, January 9th. Chardan Capital upgraded Xenon Pharmaceuticals to a “strong-buy” rating in a report on Wednesday, November 19th. Wolfe Research began coverage on Xenon Pharmaceuticals in a research report on Monday. They set an “outperform” rating and a $60.00 target price on the stock. Finally, Stifel Nicolaus set a $66.00 target price on shares of Xenon Pharmaceuticals in a report on Tuesday, February 10th. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average target price of $55.17.

Xenon Pharmaceuticals Trading Up 0.8%

NASDAQ XENE opened at $44.92 on Friday. The stock has a market cap of $3.47 billion, a PE ratio of -11.55 and a beta of 0.96. Xenon Pharmaceuticals Inc. has a 12 month low of $26.74 and a 12 month high of $46.60. The company’s 50-day moving average price is $42.51 and its 200-day moving average price is $40.94.

Xenon Pharmaceuticals (NASDAQ:XENE) last issued its earnings results on Thursday, February 26th. The biopharmaceutical company reported ($1.31) EPS for the quarter, missing analysts’ consensus estimates of ($1.20) by ($0.11). During the same period last year, the company posted ($0.84) EPS. As a group, sell-side analysts forecast that Xenon Pharmaceuticals Inc. will post -3.1 earnings per share for the current year.

Insider Transactions at Xenon Pharmaceuticals

In other Xenon Pharmaceuticals news, CEO Ian Mortimer sold 40,000 shares of the firm’s stock in a transaction on Friday, January 2nd. The stock was sold at an average price of $44.43, for a total transaction of $1,777,200.00. Following the transaction, the chief executive officer directly owned 6,000 shares in the company, valued at $266,580. This trade represents a 86.96% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Insiders sold a total of 65,205 shares of company stock valued at $2,919,762 over the last quarter. 4.07% of the stock is owned by corporate insiders.

Xenon Pharmaceuticals Company Profile

Xenon Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel, small‐molecule drugs targeting ion channels in the central and peripheral nervous system. The company’s research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion‐channel proteins to restore normal neuronal function. Xenon’s scientific platform draws upon advances in ion‐channel biology and structure‐based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company’s pipeline comprises multiple preclinical and clinical programs.